New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides

Journal of Medical Genetics
Yuting ZhaiDongye Li

Abstract

Sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) is a target of interest in gene therapy for heart failure with reduced ejection fraction (HFrEF). However, the results of an important clinical study, the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, were controversial. Promising results were observed in the CUPID 1 trial, but the results of the CUPID 2 trial were negative. The factors that caused the controversial results remain unclear. Importantly, enrolled patients were required to have a higher plasma level of B-type natriuretic peptide (BNP) in the CUPID 2 trial. Moreover, BNP was shown to inhibit SERCA2a expression. Therefore, it is possible that high BNP levels interact with treatment effects of SERCA2a gene transfer and accordingly lead to negative results of CUPID 2 trial. From this point of view, effects of SERCA2a gene therapy should be explored in heart failure with preserved ejection fraction, which is characterised by lower BNP levels compared with HFrEF. In this review, we summarise the current knowledge of SERCA2a gene therapy for heart failure, analyse potential interaction between BNP levels and therapeutic effects of SERCA2a gene transfer a...Continue Reading

References

Jun 1, 1996·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M FleschM Böhm
Aug 26, 1998·Journal of the American College of Cardiology·B S CainA H Harken
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·M I MiyamotoR J Hajjar
Mar 22, 2001·International Journal of Cardiology·R A de BoerD J van Veldhuisen
Jan 24, 2002·Nature·Donald M Bers
Mar 19, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Sudhish MishraHani N Sabbah
Jul 3, 2003·Nature Reviews. Molecular Cell Biology·David H MacLennan, Evangelia G Kranias
May 7, 2004·The New England Journal of Medicine·Michael R ZileWilliam H Gaasch
Jun 26, 2004·Circulation Research·David A KassWalter J Paulus
Dec 4, 2004·The Journal of Clinical Investigation·Patrick MostWalter J Koch
Apr 19, 2006·Circulation·Loek van HeerebeekWalter J Paulus
Nov 9, 2007·Annual Review of Physiology·Donald M Bers
Mar 18, 2008·Journal of the American College of Cardiology·Yoshiaki KawaseRoger J Hajjar
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kazuo NiwanoMasahiko Kurabayashi
Mar 31, 2009·Journal of Cardiac Failure·Brian E JaskiUNKNOWN Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators
May 8, 2010·Journal of the American College of Cardiology·Andreas KalogeropoulosUNKNOWN Health ABC Study Investigators
May 13, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lahouaria HadriRoger J Hajjar
Aug 17, 2010·Basic Research in Cardiology·Karl ToischerGerd Hasenfuss
Jun 29, 2011·Circulation·Mariell JessupUNKNOWN Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators
Jul 2, 2011·Journal of the American College of Cardiology·Donald E SelbyMarkus Meyer
Jul 8, 2011·The New England Journal of Medicine·C M O'ConnorR M Califf
Sep 9, 2011·Nature·Changwon KhoRoger J Hajjar
Jun 9, 2012·Circulation Research·Evangelia G Kranias, Roger J Hajjar

❮ Previous
Next ❯

Citations

Jul 25, 2019·Heart·Nick B SpathScott I K Semple
Jan 6, 2021·Pflügers Archiv : European journal of physiology·Satadru K LahiriXander H T Wehrens

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.